Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?

• Published in: Translational research : the journal of laboratory and clinical medicine Vol. 151; no. 5; pp. 240 - 245
• Main Authors: Subirá, Dolores, Font, Patricia, Villalón, Lucia, Serrano, Cristina, Askari, Elham, Góngora, Elena, Castañón, Susana, Gonzalo, Raquel, Mata, Raquel, Román, Alejandro, Llamas, Pilar
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 01.05.2008
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow Cells - immunology; Bone Marrow Cells - pathology; CD2 Antigens - analysis; CD56 Antigen - analysis; Diagnosis, Differential; Female; Flow Cytometry; Humans; Immunophenotyping - methods; Internal Medicine; Leukemia, Myelomonocytic, Chronic - diagnosis; Leukemia, Myelomonocytic, Chronic - immunology; Leukocyte Common Antigens - analysis; Male; Middle Aged; Monocytes - immunology; Monocytes - pathology; Myelodysplastic Syndromes - diagnosis; Myelodysplastic Syndromes - immunology; Myeloproliferative Disorders - diagnosis; Myeloproliferative Disorders - immunology; MPD; white blood cell; World Health Organization; FAB; refractory cytopenia with multilineage dysplasia; BM; myeloproliferative diseases; FCI; bone marrow; RCMD; CMML; myelodysplastic syndromes; WBC; French-American-British; flow cytometry immunophenotyping; MDS; chronic myelomonocytic leukemia; WHO
• ISSN: 1931-5244; 1878-1810
• DOI: 10.1016/j.trsl.2008.03.001

Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease balanced between myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD). We used flow cytometry to describe and compare the immunophenotypic profile of 20 patients with CMML, 38 patients with MDS, and 20 patients with MPD. CMML and MDS only showed statistically significant differences ( P < 0.05) in CD56 monocyte expression. CMML and MPD showed significant differences in CD45 myeloid distribution, myeloid antigenic profile, CD56 and CD2 monocyte expression, and B-cell development. These data support the classic concept of CMML as part of MDS diseases and encourage including immunophenotyping among the studies to be performed in these diseases.